NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd

ClaSPd

NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd)

NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd)

The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.

Sponsor

Weill Medical College of Cornell University

Collaborator

Karyopharm Therapeutics Inc

---

ClinicalTrials.gov Identifier: NCT04843579

Official Title: A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

First Posted : April 13, 2021

Click here for ClinicalTrials.gov

---

Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information

---

Drug: Selinexor

Drug: Clarithromycin

Drug: Pomalidomide

Drug: Dexamethasone

---

Locations

United States, New York